This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Spectrum Announces Launch Of New Patient-to-Patient Educational Campaign For ZEVALIN® On

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with a primary focus in oncology and hematology, announced today the launch of the Company's new patient campaign for ZEVALIN (ibritumomab tiuxetan) Injection for Intravenous Use, on debuts four multimedia patient stories from actual patients living with follicular lymphoma and treated with ZEVALIN. Jan W., Laura T., Michael W., and Dave S. all share their perspectives on life before cancer, diagnoses, treatment options, receiving ZEVALIN, and life today. has been completely redesigned to also become an educational resource for patients, caregivers, and healthcare professionals seeking information on follicular lymphoma and ZEVALIN. While the overall re-launch campaign will continue to focus on physicians with "RRZ" (rituximab, rituximab, ZEVALIN), additional emphasis will be placed on direct-to-patient outreach and patient-to-patient education.

“The stories of these patients on are very moving and reinforce the centrality of patients in the mission of our company,” said Rajesh C. Shrotriya, MD, Chairman, Chief Executive Officer and President of Spectrum Pharmaceuticals, Inc. “Patients today are more empowered through education to take an active role in learning about their treatment options. These four patients and their doctors chose ZEVALIN. We hope their journeys will inspire and encourage other follicular lymphoma patients to take an active role in educating themselves. Follicular lymphoma patients deserve to understand all of their options, including how one therapeutic dose of ZEVALIN could fit into their treatment plans.”

This initiative is part of a larger patient-to-patient campaign supported by print, digital, online, and personalized patient educational programs. More than ever patients are going online to learn about their disease and treatment options. has been redesigned in part to provide a forum for patients and caregivers to learn more from other patients living with follicular lymphoma and treated with ZEVALIN.

About ZEVALIN ® and the ZEVALIN Therapeutic Regimen

ZEVALIN (ibritumomab tiuxetan) Injection for intravenous use, is indicated for the treatment of patients with relapsed or refractory, low-grade or follicular B-cell non-Hodgkin’s lymphoma (NHL). ZEVALIN is also indicated for the treatment of patients with previously untreated follicular non-Hodgkin Lymphoma who achieve a partial or complete response to first-line chemotherapy.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,692.18 +13.95 0.08%
S&P 500 2,058.74 +2.59 0.13%
NASDAQ 4,879.3660 +16.0040 0.33%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs